540 related articles for article (PubMed ID: 14971891)
1. Synthesis and chemical-pharmacological characterization of the antimetastatic NAMI-A-type Ru(III) complexes (Hdmtp)[trans-RuCl4(dmso-S)(dmtp)], (Na)[trans-RuCl4(dmso-S)(dmtp)], and [mer-RuCl3(H2O)(dmso-S)(dmtp)] (dmtp = 5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidine).
Velders AH; Bergamo A; Alessio E; Zangrando E; Haasnoot JG; Casarsa C; Cocchietto M; Zorzet S; Sava G
J Med Chem; 2004 Feb; 47(5):1110-21. PubMed ID: 14971891
[TBL] [Abstract][Full Text] [Related]
2. Reduction of in vivo lung metastases by dinuclear ruthenium complexes is coupled to inhibition of in vitro tumour invasion.
Bergamo A; Stocco G; Casarsa C; Cocchietto M; Alessio E; Serli B; Zorzet S; Sava G
Int J Oncol; 2004 Feb; 24(2):373-9. PubMed ID: 14719114
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, structural characterization, solution chemistry, and preliminary biological studies of the ruthenium(III) complexes [TzH][trans-RuCl4(Tz)2] and [TzH][trans-RuCl4(DMSO)(Tz)].(DMSO), the thiazole analogues of antitumor ICR and NAMI-A.
Mura P; Camalli M; Messori L; Piccioli F; Zanello P; Corsini M
Inorg Chem; 2004 Jun; 43(13):3863-70. PubMed ID: 15206867
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, characterization, antiproliferative and anti-metastatic properties of two ruthenium-DMSO complexes containing 2,2'-biimidazole.
Tan C; Hu S; Liu J; Ji L
Eur J Med Chem; 2011 May; 46(5):1555-63. PubMed ID: 21354673
[TBL] [Abstract][Full Text] [Related]
5. Ruthenium-based NAMI-A type complexes with in vivo selective metastasis reduction and in vitro invasion inhibition unrelated to cell cytotoxicity.
Bergamo A; Gava B; Alessio E; Mestroni G; Serli B; Cocchietto M; Zorzet S; Sava G
Int J Oncol; 2002 Dec; 21(6):1331-8. PubMed ID: 12429985
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, characterization, and in vitro evaluation of novel ruthenium(II) eta6-arene imidazole complexes.
Vock CA; Scolaro C; Phillips AD; Scopelliti R; Sava G; Dyson PJ
J Med Chem; 2006 Sep; 49(18):5552-61. PubMed ID: 16942028
[TBL] [Abstract][Full Text] [Related]
7. In vitro cell cycle arrest, in vivo action on solid metastasizing tumors, and host toxicity of the antimetastatic drug NAMI-A and cisplatin.
Bergamo A; Gagliardi R; Scarcia V; Furlani A; Alessio E; Mestroni G; Sava G
J Pharmacol Exp Ther; 1999 Apr; 289(1):559-64. PubMed ID: 10087050
[TBL] [Abstract][Full Text] [Related]
8. The hydrolysis mechanism of the anticancer ruthenium drugs NAMI-A and ICR investigated by DFT-PCM calculations.
Vargiu AV; Robertazzi A; Magistrato A; Ruggerone P; Carloni P
J Phys Chem B; 2008 Apr; 112(14):4401-9. PubMed ID: 18348562
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity relationships for NAMI-A-type complexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = imidazole, indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl-1,2,4-triazole): aquation, redox properties, protein binding, and antiproliferative activity.
Groessl M; Reisner E; Hartinger CG; Eichinger R; Semenova O; Timerbaev AR; Jakupec MA; Arion VB; Keppler BK
J Med Chem; 2007 May; 50(9):2185-93. PubMed ID: 17402720
[TBL] [Abstract][Full Text] [Related]
10. Dual Action of NAMI-A in inhibition of solid tumor metastasis: selective targeting of metastatic cells and binding to collagen.
Sava G; Zorzet S; Turrin C; Vita F; Soranzo M; Zabucchi G; Cocchietto M; Bergamo A; DiGiovine S; Pezzoni G; Sartor L; Garbisa S
Clin Cancer Res; 2003 May; 9(5):1898-905. PubMed ID: 12738748
[TBL] [Abstract][Full Text] [Related]
11. Osmium NAMI-A analogues: synthesis, structural and spectroscopic characterization, and antiproliferative properties.
Cebrián-Losantos B; Krokhin AA; Stepanenko IN; Eichinger R; Jakupec MA; Arion VB; Keppler BK
Inorg Chem; 2007 Jun; 46(12):5023-33. PubMed ID: 17497853
[TBL] [Abstract][Full Text] [Related]
12. Lack of In vitro cytotoxicity, associated to increased G(2)-M cell fraction and inhibition of matrigel invasion, may predict In vivo-selective antimetastasis activity of ruthenium complexes.
Zorzet S; Bergamo A; Cocchietto M; Sorc A; Gava B; Alessio E; Iengo E; Sava G
J Pharmacol Exp Ther; 2000 Dec; 295(3):927-33. PubMed ID: 11082425
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and reactivity of the aquation product of the antitumor complex trans-[Ru(III)Cl4(indazole)2]-.
Cebrián-Losantos B; Reisner E; Kowol CR; Roller A; Shova S; Arion VB; Keppler BK
Inorg Chem; 2008 Jul; 47(14):6513-23. PubMed ID: 18553904
[TBL] [Abstract][Full Text] [Related]
14. Appraisal of the redox behaviour of the antimetastatic ruthenium(III) complex [ImH][RuCl(4)(DMSO)(Im)], NAMI-A.
Ravera M; Baracco S; Cassino C; Zanello P; Osella D
Dalton Trans; 2004 Aug; (15):2347-51. PubMed ID: 15278129
[TBL] [Abstract][Full Text] [Related]
15. Ruthenium(III) dimethyl sulfoxide pyridinehydroxamic acid complexes as potential antimetastatic agents: synthesis, characterisation and in vitro pharmacological evaluation.
Griffith D; Cecco S; Zangrando E; Bergamo A; Sava G; Marmion CJ
J Biol Inorg Chem; 2008 May; 13(4):511-20. PubMed ID: 18183430
[TBL] [Abstract][Full Text] [Related]
16. Effects of the Ru(III) complexes [mer-RuCl3(DMSO)2Im]degrees and Na[trans-RuCl4(DMSO)Im] on solid mouse tumors.
Sava G; Pacor S; Mestroni G; Alessio E
Anticancer Drugs; 1992 Feb; 3(1):25-31. PubMed ID: 1623212
[TBL] [Abstract][Full Text] [Related]
17. Tuning of redox potentials for the design of ruthenium anticancer drugs -- an electrochemical study of [trans-RuCl(4)L(DMSO)](-) and [trans-RuCl(4)L(2)](-) complexes, where L = imidazole, 1,2,4-triazole, indazole.
Reisner E; Arion VB; Guedes da Silva MF; Lichtenecker R; Eichinger A; Keppler BK; Kukushkin VY; Pombeiro AJ
Inorg Chem; 2004 Nov; 43(22):7083-93. PubMed ID: 15500346
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and X-ray Structural Analysis of the Ruthenium(III) Complex Na[trans-RuCl4(DMSO) (PyrDiaz)], the Diazene Derivative of Antitumor NAMI-Pyr.
Vajs J; Pevec A; Gazvoda M; Urankar D; Goreshnik E; Polanc S; Košmrlj J
Acta Chim Slov; 2017 Dec; 64(4):763-770. PubMed ID: 29318318
[TBL] [Abstract][Full Text] [Related]
19. Combined therapy of the antimetastatic compound NAMI-A and electroporation on B16F1 tumour cells in vitro.
Bicek A; Turel I; Kanduser M; Miklavcic D
Bioelectrochemistry; 2007 Nov; 71(2):113-7. PubMed ID: 17602896
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of B16 melanoma metastases with the ruthenium complex imidazolium trans-imidazoledimethylsulfoxide-tetrachlororuthenate and down-regulation of tumor cell invasion.
Gava B; Zorzet S; Spessotto P; Cocchietto M; Sava G
J Pharmacol Exp Ther; 2006 Apr; 317(1):284-91. PubMed ID: 16368900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]